Pemetrexed + Carboplatin + PEMBROLIZUMAB + CISPLATIN for adenocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 10 Sep 2018: Trial registered, NCT03664024
  2. 30 Oct 2018: Trial started, NCT03664024

The trials

NCT03664024: Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)

State
Completed
Phase
Phase 2
People
118 taking part
Started
30 Oct 2018
Primary completion
5 Nov 2021
Arms
Pembrolizumab Standard of Care
Results
Posted on the registry
  1. 10 Sep 2018: Trial registered
  2. 30 Oct 2018: Trial started
  3. 5 Nov 2021: Trial completed
  4. 14 Nov 2022: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.